This site is intended only for healthcare professionals resident in the Republic of Ireland
Menu
Close
This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Menu
Close
Real World Evidence
The information on this website is based on data from adult patients with ALK (anaplastic lymphoma kinase)-positive / ROS 1-positive advanced NSCLC (non small cell lung cancer) treated with XALKORI®(crizotinib), produced in line with the XALKORI®(crizotinib) Summary of Product Characteristics. XALKORI® (crizotinib) Prescribing Information click here. Adverse event reporting information can be found at the bottom of the page.
A Phase 1, single-arm study evaluating the efficacy and safety of XALKORI® in patients with ROS1+ advanced NSCLC (n=53)1
A Phase 3 study evaluating the efficacy and safety of XALKORI® vs. chemotherapy as first-line therapy for ALK+ advanced NSCLC (n=343)2
The safety of XALKORI® has been evaluated in 1,722 patients, including patients with ALK+ (n=1,669) advanced NSCLC and ROS1+ advanced NSCLC (n=53)3
ALK: anaplastic lymphoma kinase, NSCLC: non-small cell lung cancer
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.
Copyright © 2024 Pfizer Limited. All rights reserved.
The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.
I confirm that I am a healthcare professional* resident in the Republic of Ireland.
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses
Terms of use
PP-UNP-IRL-0784. June 2024